FindTrial
Sign In

The role and mechanism of GPX4/MYOC in osteoarthritis pathogenesis

The role and mechanism of GPX4/MYOC in osteoarthritis pathogenesis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100051045
Enrollment
Unknown
Registered
2021-09-10
Start date
2021-10-01
Completion date
Unknown
Last updated
2022-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

Non-leision group:Nil
damaged group:Nil

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with knee arthritis undergoing knee arthroplasty; 2. Patients with traumatic thigh amputation.

Exclusion criteria

Exclusion criteria: 1. Known metabolic or bone related diseases other than OA, such as renal dysfunction, thyroid or parathyroid diseases, malignant tumors, etc; 2. Other diseases that will affect bone structure and bone quality, such as rheumatoid arthritis; 3. Taking drugs that can affect bone metabolism, such as anti bone resorption drugs, calcitonin, thyroxine, parathyroid hormone and sex hormone replacement therapy; 4. History of femoral or tibial osteotomy.

Design outcomes

Primary

MeasureTime frame
Immunohistochemistry;—

Countries

China

Contacts

Public ContactLi Guangyi

Shanghai Sixth People's Hospital

guangyi.li@shsmu.edu.cn+86 21 64369181

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026